IDEXX LABORATORIES INC /DE
$700.65
−3.58 (−0.51%) · delayed · Nov 16, 2026
Five-year price
52w $500.61 to $769.98
- Market cap
- $55.2B
- Enterprise value
- $55.5B
- P/E
- 53.6×
- 62.2× on 3y avg EPS
- EV / EBIT
- 40.8×
- FCF yield
- 1.9%
- ROIC
- 58.0%
- Debt / equity
- 0.28
- Piotroski F
- 8/9
Value scorecard · FY2025
Does it pass the value tests?
Quality
- ●ROIC > 12% (5y avg)5y avg ROIC 53.3%
- ●ROE > 15% (5y avg)5y avg ROE 79.6%
- ●Stable operating marginsMargin volatility 1.6% (σ, 5y)
- ●Earnings convert to cashFCF / net income 85% (5y avg)
- ●Growing revenueRevenue CAGR 5y 9.7%
- ●Shrinking share countDiluted shares -6.6% over 5y
Value
- ○P/E below 15P/E 53.6
- ○EV/EBIT below 12EV/EBIT 40.8
- ○FCF yield above 6%FCF yield 1.9%
- ○Price below Graham NumberGraham Number $77.44
- ○P/B below 3P/B 34.4
Safety
- ●Debt / equity below 0.5D/E 0.28
- ●Debt payable in < 4 yrs of earningsNet debt $0.3B
- ●Interest coverage > 8xCoverage 35.0x
- ○Current ratio > 1.5Current ratio 1.23
- ●Piotroski F-score ≥ 6F-score 8/9
Graham Defensive
- ●Adequate size (revenue > $2B)Revenue $4.3B
- ○Strong condition (current ratio ≥ 2)Current ratio 1.23
- ●Earnings stability (no loss, 10y)10 years of data
- ○Uninterrupted dividendsDividends paid every year on record
- ●Earnings growth ≥ 33% (10y, 3y avgs)EPS growth 251%
- ○Moderate P/E (≤ 15 on 3y avg EPS)P/E (3y avg) 62.2
- ○P/E × P/B ≤ 22.5Product 2137.7
Valuation lab
What do you have to believe?
At $700.65, the market is pricing in about 18.5% annual free-cash-flow growth for the next decade (9% discount rate, 2.5% terminal growth).
Starting cash flow
Net debt $270M · 79M shares · 5y revenue CAGR 9.7%
Intrinsic value
$369.53
Price
$700.65
Premium paid
90%
What the price implies
The market is paying for 18.5% annual cash-flow growth for 10 years at a 9.0% discount rate.
Terminal value share
62% of the value sits beyond year 10.
Financial statements
A decade of the record.
USD millions · fiscal years · source: SEC 10-K XBRL
| Line item | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,775 | 1,969 | 2,213 | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 |
| Gross profit | 975 | 1,097 | 1,242 | 1,366 | 1,571 | 1,889 | 2,004 | 2,190 | 2,379 | 2,660 |
| Operating income | 350 | 413 | 491 | 553 | 695 | 932 | 899 | 1,097 | 1,128 | 1,360 |
| Operating margin | 19.7% | 21.0% | 22.2% | 23.0% | 25.7% | 29.0% | 26.7% | 30.0% | 29.0% | 31.6% |
| Pre-tax income | 322 | 381 | 458 | 522 | 662 | 903 | 860 | 1,061 | 1,110 | 1,324 |
| Income tax | 100 | 118 | 81 | 94 | 80 | 158 | 181 | 216 | 222 | 265 |
| Net income | 222 | 263 | 377 | 428 | 582 | 745 | 679 | 845 | 888 | 1,059 |
| EPS (diluted) | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | 8.60 | 8.03 | 10.06 | 10.67 | 13.08 |
| Diluted shares | 91 | 90 | 88 | 88 | 87 | 87 | 85 | 84 | 83 | 81 |
Who owns it